Chengye Medical's Key Subsidiary Fukan Vitality Pharmaceutical Announces Board Resolution on Cash Capital Increase and New Share Issuance
Key facts
- Chengye Medical's Key Subsidiary Fukan Vitality Pharmaceutical Announces Board Resolution on Cash Capital Increase and New Share Issuance
- Fukan Vitality Pharmaceutical Co., Ltd., a key subsidiary of Chengye Medical, has announced a board resolution on June 26, 2025, to issue new shares via a cash capital increase. The total issuance amount is NT$77,466,400, comprising 880,300 ordinary shares, with proceeds allocated to strengthen operational funding.
- Source: PR Times
- Date: June 26, 2026
Direct answer
Fukan Vitality Pharmaceutical Co., Ltd., a key subsidiary of Chengye Medical, has announced a board resolution on June 26, 2025, to issue new shares via a cash capital increase. The total issuance amount is NT$77,466,400, comprising 880,300 ordinary shares, with proceeds allocated to strengthen operational funding.
- Citation
- Chengye Medical's Key Subsidiary Fukan Vitality Pharmaceutical Announces Board Resolution on Cash Capital Increase and New Share Issuance (June 26, 2026), PR Times
- Source
- PR Times
- Date
- June 26, 2026
Fukan Vitality Pharmaceutical Co., Ltd., a key subsidiary of Chengye Medical, has announced a board resolution on June 26, 2025, to issue new shares via a cash capital increase. The total issuance amount is NT$77,466,400, comprising 880,300 ordinary shares, with proceeds allocated to strengthen operational funding.
📋 Article Processing Timeline
- 📰 Published: June 26, 2026 at 09:00
- 🔍 Collected: June 27, 2026 at 17:00 (32h 0m after Published)
- 🤖 AI Analyzed: June 27, 2026 at 18:01 (1h 1m after Collected)
1. Board resolution date: 115/06/26
2. Source of capital increase: Issuance of new shares via cash capital increase
3. Whether the issuance of new shares is under a comprehensive filing (if yes, specify the planned issuance period; if no): No
4. Total issuance amount and number of shares (for capital increases from retained earnings or reserves, exclude shares allocated to employees): Total issuance amount of NT$77,466,400, 880,300 ordinary shares
5. Issuance amount and number of shares for this round under a comprehensive filing: Not applicable
6. Remaining amount and number of shares after this issuance under a comprehensive filing: Not applicable
7. Par value per share: NT$10
8. Issue price: NT$88
9. Number of shares for employee subscription or allocation amount: 88,030 shares
10. Number of publicly offered shares: Not applicable
11. Subscription or free allocation ratio for existing shareholders: 90%
12. Handling of fractional shares and unclaimed shares after the subscription deadline: Authorized for the Chairman to arrange subscriptions with specific individuals
13. Rights and obligations of the newly issued shares: Same rights and obligations as existing shares
14. Use of capital increase funds: To strengthen operational funding
15. Rationality and necessity of fundraising after a cash reduction in capital (applicable if cash reduction was conducted in the current or previous year): Not applicable
16. Other matters to be disclosed: None
2. Source of capital increase: Issuance of new shares via cash capital increase
3. Whether the issuance of new shares is under a comprehensive filing (if yes, specify the planned issuance period; if no): No
4. Total issuance amount and number of shares (for capital increases from retained earnings or reserves, exclude shares allocated to employees): Total issuance amount of NT$77,466,400, 880,300 ordinary shares
5. Issuance amount and number of shares for this round under a comprehensive filing: Not applicable
6. Remaining amount and number of shares after this issuance under a comprehensive filing: Not applicable
7. Par value per share: NT$10
8. Issue price: NT$88
9. Number of shares for employee subscription or allocation amount: 88,030 shares
10. Number of publicly offered shares: Not applicable
11. Subscription or free allocation ratio for existing shareholders: 90%
12. Handling of fractional shares and unclaimed shares after the subscription deadline: Authorized for the Chairman to arrange subscriptions with specific individuals
13. Rights and obligations of the newly issued shares: Same rights and obligations as existing shares
14. Use of capital increase funds: To strengthen operational funding
15. Rationality and necessity of fundraising after a cash reduction in capital (applicable if cash reduction was conducted in the current or previous year): Not applicable
16. Other matters to be disclosed: None
FAQ
How much is Fukan Vitality Pharmaceutical's capital increase?
NT$77,466,400 by issuing 880,300 new shares.
What will the raised funds be used for?
Entirely for operational capital to enhance production and supply.
Can employees purchase shares?
Yes, 88,030 shares are allocated for employee subscription.